Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT03214562
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Adello Biologics, LLC
- Target Recruit Count
- 102
- Registration Number
- NCT03202927
- Locations
- 🇺🇸
Celerion Inc., Lincoln, Nebraska, United States
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 333
- Registration Number
- NCT03197935
- Locations
- 🇩🇪
Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany
🇬🇧Leicester Royal Infirmary, Leicester, United Kingdom
🇦🇺Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT03147612
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
- Conditions
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03102606
- Locations
- 🇺🇸
Stanford University School of Medicine - Cancer Institute, Stanford, California, United States
🇺🇸Hematology/Oncology of the North Shore, Skokie, Illinois, United States
🇨🇳Heilongjiang Cancer Hospital, Harbin, Heilongjiang, China
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2018-01-19
- Target Recruit Count
- 34
- Registration Number
- NCT02983097
- Locations
- 🇩🇪
LMU Klinikum München-Großhadern, München, Germany
🇩🇪Diakonie Krankenhaus Bremen, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Germany
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 237
- Registration Number
- NCT02953340
- Locations
- 🇺🇸
Millennium Oncology, Pembroke Pines, Florida, United States
🇺🇸Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
🇺🇸Lakes Research, LLC, Miami Lakes, Florida, United States
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
- Conditions
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 18
- Registration Number
- NCT02943733
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
- Conditions
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT02909036
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 37
- Registration Number
- NCT02834403
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.